Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;24(6):e13977.
doi: 10.1111/tid.13977. Epub 2022 Nov 11.

Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021

Camille N Kotton  1 , Julián Torre-Cisneros  2   3 ; International CMV Symposium Faculty; José Maria Aguado  4 , Sophie Alain  5 , Fausto Baldanti  6 , Gabriele Baumann  7 , Udo Boeken  8 , Maria de la Calle  9 , Javier Carbone  10 , Fabio Ciceri  11 , Patrizia Comoli  12 , Lionel Couzi  13 , Lara Danziger-Isakov  14 , Mario Fernández-Ruiz  15 , Corrado Girmenia  16 , Paolo Antonio Grossi  17 , Hans H Hirsch  18 , Atul Humar  19 , Nassim Kamar  20 , Camille Kotton  21 , Per Ljungman  22 , Michele Malagola  23 , Estefania Mira  24 , Nicolas Mueller  25 , Martina Sester  26 , Chieh-Lin Jerry Teng  27 , Julian Torre-Cisneros  24 , Piedad Ussetti  28 , Glen Westall  29 , Dana Wolf  30 , Marty Zamora  31
Affiliations
Review

Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021

Camille N Kotton et al. Transpl Infect Dis. 2022 Dec.

Abstract

The CMV Symposium in September 2021 was an international conference dedicated to cytomegalovirus (CMV) infection after solid organ or hematopoietic stem cell transplantation. This review provides an overview of the presentations given by the expert faculty, supplemented with educational clinical cases. Topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV-specific immunity and management of CMV in transplant settings. Major advances in the prevention and treatment of CMV in the past decade and increased understanding of CMV immunity have led to improved patient outcomes. In the future, management algorithms may be individualized based on the transplant recipient's immune profile, which will mark the start of a new era for patients with CMV.

Keywords: cellular therapy; cytomegalovirus immunoglobulin (CMVIG); hematopoietic stem cell transplant; prophylaxis; solid organ transplant; treatment; vaccine.

PubMed Disclaimer

Conflict of interest statement

The international CMV symposium faculty

José Maria Aguado: Honoraria for speaking or participating in Advisory Boards and/or research grants from Biotest, Gilead Sciences, MSD, Pfizer, Roche. Sophie Alain: Research funding as a scientific expert or site principal investigator from Altona, Biotest, BioMérieux, Qiagen, Hologic, GlaxoSmithKline, Merck, MSD, Shire (a Takeda Company). Scientific expert/Advisory board member for the QCMD. ANSM expert for delivery of anti‐CMV for compassionate use in refractory/resistant patients. Fausto Baldanti: Consultant for: Biotest, Takeda, Qiagen, Roche, MSD; Research support by: DiaSorin, NTP, Qiagen, Elitech. Udo Boeken: Consultant and speaker for Biotest. Javier Carbone: Speaker/Advisory Board member for Biotest, Grifols and LFB. Research funding from Biotest, Grifols and Takeda. Patrizia Comoli: Speaker/Advisory Board member for Atara Biotherapeutics and Pierre Fabre Pharma. Lionel Couzi: Grants from Astellas and Novartis. Lecture fees from Astellas, Biotest, Chiesi, GSK, Novartis, Ostuka, Sandoz. Consultancy fees from Biotest, Hansa and Novartis. Travel funding from Astellas, Chiesi, Novartis, Sandoz and Vifor. Lara Danziger‐Isakov: Consultant for Merck and Takeda and contracted clinical research with Ansun BioPharma, Astellas, Merck, Pfizer, Viracor and Takeda. Recipient of grant from NIH. Corrado Girmenia: Speaker/Advisory Board member for AbbVie, Amgen, Biotest, Gilead Sciences, Janssen, MSD, Novartis Pharma, Sanofi and Takeda. Paolo Grossi: Advisory Board member for Allovir, Biotest, Gilead Sciences, MSD and Takeda. Speaker's bureau for Atara, Biotest, Gilead Sciences, MSD, Shionogi and Takeda. Hans H. Hirsch: Consultant honoraria from Molecular Probes and Roche Diagnostics and Speaker honoraria from Gilead Sciences. Atul Humar: Research support from Astellas, Roche, Qiagen. Advisory Board member: Merck, Takeda. Nassim Kamar: Speaker/Advisory Board member for AbbVie, Astellas, Astrazeneca, Biotest, CSL Behring, Chiesi, Gilead Sciences, Fresenius Medical Care, MSD, Neovvi, Novartis Pharma, Sanofi, Sandoz, Shire (a Takeda company). Per Ljungman: Advisory board/endpoint committee member for AiCuris, Merck, MSD, Takeda. Investigator with MSD. Speaker for Biotest, MSD, Takeda. Michele Malagola: Advisory Board member for Biotest and MSD. Nicolas Mueller: Advisory Board member for MSD, Pfizer and Takeda. Martina Sester: Research support/honoraria and travel support from Astellas, Biotest and Novartis. Glen Westall: Advisory Board member for CSL Behring and research study support from Qiagen. Dana Wolf: Speaker/Advisory Board member for Merck, MSD and Takeda. Recipient of research grants from GSK, MSD, and Sanofi. Marty Zamora: Consultant for CSL Behring.

References

    1. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759‐773. - PMC - PubMed
    1. Helanterä I, Kyllönen L, Lautenschlager I, Salmela K, Koskinen P. Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis. Am J Transplant. 2010;10(9):2026‐2032. - PubMed
    1. Berry R, Watson GM, Jonjic S, Degli‐Esposti MA, Rossjohn J. Modulation of innate and adaptive immunity by cytomegaloviruses. Nat Rev Immunol. 2020;20(2):113‐127. - PubMed
    1. Sester M, Sester U, Gärtner BC, Girndt M, Meyerhans A, Köhler H. Dominance of virus‐specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol. 2002;13(10):2577‐2584. - PubMed
    1. Forlanini F, Dara J, Dvorak CC, Cowan MJ, Puck JM, Dorsey MJ. Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: a new category of transplant recipients. Transpl Infect Dis. 2021;23(2):e13504. - PMC - PubMed

MeSH terms

Substances

Grants and funding